Navigation Links
Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Second Quarter Of 2013 Fiscal Year
Date:2/15/2013

JERSEY CITY, N.J., Feb. 15, 2013 /PRNewswire/ -- Aoxing Pharmaceutical Company, Inc.  (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the three and six month periods ended December 31, 2012.  Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on February 14, 2013.

Financial Results:

Revenues for the three and six months ended December 31, 2012 were $3,314,768 and $5,919,531, respectively, representing a 56% and a 62% increase over the revenues realized in the comparable periods of fiscal year 2012.  In both periods the increase in revenues led to a 60% increase in gross profit.  The increase in revenue was mainly attributable to the increase in sales of our main product, Zhongtongan, which is now being marketed for gynecological and orthopaedic applications in addition to its core pediatric and stomotological market.  Sales of Zhongtongan accounted for 93% of sales during the quarter ended December 31, 2012. 

Aoxing Pharma completed a $10.2 million financing at the end of September 2012, which allowed it to make some crucial investments in the future of its business.  Operating expenses, therefore, were swelled during the second quarter of fiscal 2013 by two categories of targeted investment:

  • Research and development ("R&D") expenses were $1,090,104 during the three months ended December 31, 2012 and $1,219,659 during the six month period then ended, in both cases representing a several fold increase over R&D expense in fiscal 2012. 
  • Selling expenses in the amount of $1,706,202 incurred during the three months ended December 31, 2012 and $2,314
    '/>"/>

SOURCE Aoxing Pharmaceutical Company, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Aoxing Pharmaceutical Company Announces Management Change
2. Aoxing Pharmaceutical Company, Inc. Declines To Comment On Market Activity
3. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For First Quarter Of 2013 Fiscal Year
4. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... LONDON , March 31, 2015 /PRNewswire/ ... drug discovery applications have driven the need ... far the automated segments are going to ... this research. This study provides the market ... profiling and key trends for the liquid ...
(Date:3/31/2015)... , Mar. 27, 2015 Research and Markets ... the "Intraoperative Imaging Market by Type (Intraoperative CT, ... report to their offering. The global ... CAGR of 3.5% from 2014 to 2019 ... to a number of forces that favor this market. ...
(Date:3/31/2015)... -- RnRMarketResearch.com adds "Pemphigus - Pipeline ... 68 pages with latest updates, data and information ... The report "Pemphigus - Pipeline Review, H1 2015" report provides ... Pemphigus , complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
Breaking Medicine Technology:Western European Liquid Handling Market 2Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market 2015-2019 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 4
... 22, 2011 ResearchDx announced today the official ... CDO. Recent FDA initiatives, such ... Co-Development Concept Paper, have spurred biopharmaceutical companies, interest ... companion diagnostics. The traditional Contract Research Organization (CRO), ...
... OMER ) today announced that its exclusive license to ... been amended to include addiction and compulsive disorders in the ... Company,s discovery of a previously unknown link between PDE7 and ... it also is the first to link PDE7 to any ...
Cached Medicine Technology:ResearchDx Launches Contract Diagnostics Organization (CDO) 2Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 2Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 3Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 4
(Date:3/31/2015)... March 31, 2015 QMedET Solutions, ... 2, bringing the industry’s most advanced speech recognition ... community. Physicians can now experience the full benefits ... source, offering value-added support services that ensure successful ... , “QMedET is proud to provide Dragon Medical ...
(Date:3/31/2015)... The Oliver Law Group P.C. has launched ... client requests after Zofran lawsuits were filed in Massachusetts ... failed to warn physicians and their patients about the ... “illegally and fraudently” promoted Zofran as a treatment to ... that use from the U.S. Food and Drug Administration. ...
(Date:3/31/2015)... 31, 2015 The status of more ... discussed during a Case Management Conference scheduled to be ... New York on April 21st. According to court documents, ... litigation established for Mirena lawsuits filed on behalf of ... other serious complications related to the birth control device. ...
(Date:3/31/2015)... IL (PRWEB) March 31, 2015 Rising ... athletes have forced researchers and surgeons to better analyze ... the tissues used for repair. A recent study ... utilized a systematic review of 1,016 young, very active ... autograft tissues. , “This is the first review ...
(Date:3/31/2015)... These two automakers will address an audience of 400+ ... a shift that has become apparent in the motor ... for the insurance carriers alone. With connected car tech. ... in store for them. , Beyond more ... to their own involvement in the insurance process and ...
Breaking Medicine News(10 mins):Health News:QMedET Solutions Announces Addition of Dragon® Medical Practice Edition 2 to its Roster of Products 2Health News:Zofran Lawsuit Information Page Launched In Response To Clients Request For Information On Potential For Zofran Birth Defects, The Olive Law Group 2Health News:Zofran Lawsuit Information Page Launched In Response To Clients Request For Information On Potential For Zofran Birth Defects, The Olive Law Group 3Health News:Mirena IUD Lawsuits Move Forward as Federal Court Readies to Convene Next Case Management Conference 2Health News:Mirena IUD Lawsuits Move Forward as Federal Court Readies to Convene Next Case Management Conference 3Health News:ACL Failure Risks Increased in Young Patients Using Allografts 2Health News:TU-Automotive: Fiat and Renault-Nissan at the Centre of a Motor Insurance Evolution 2
... Donate Life California Organ & Tissue Donor Registry Reaches 2 ... Million Registrations ... Less Likely to Register, SACRAMENTO, Calif., Oct. 9 More than ... the,state,s Donate Life California Organ & Tissue Donor Registry, doubling the,state,s number ...
... Oct. 9 House Republican Whip Roy,Blunt (Mo.) ... Whip,James Clyburn (D-S.C.) yesterday suggested on CNN that ... override the president,s veto of the,SCHIP bill:, ... will be,hard-pressed to override the president,s veto of ...
... BOSTON--Like a crossword-puzzle solver who uses the letters in ... Cancer Institute and an international group of collaborators have ... breast cancer to identify a gene linked to non-hereditary ... a study posted online by the journal Nature Genetics, ...
... Pantoliano,reveals a personal history of depression and his ... in a guest blog entry, http://www.nami.org/blog published ... Pantoliano,s entry comes during Mental Illness Awareness ... opening of his latest film, CANVAS, http://www.canvasthefilm.com ...
... drinking and helped to boost abstinence, study finds , , ... to treat epileptic seizures could be added to the ... their addiction, a new study suggests. , The drug ... alcoholics stay away from heavy drinking, the study authors ...
... study is needed, and the therapy is valuable , , ... receiving androgen-deprivation therapy, a common form of hormone treatment ... face a nearly threefold higher risk of dying from ... danger results from a drop in testosterone levels that ...
Cached Medicine News:Health News:Two Million Californians Say 'Yes!' to Organ and Tissue Donation 2Health News:Two Million Californians Say 'Yes!' to Organ and Tissue Donation 3Health News:Two Million Californians Say 'Yes!' to Organ and Tissue Donation 4Health News:'Network' approach identifies potential breast cancer susceptibility gene 2Health News:'Network' approach identifies potential breast cancer susceptibility gene 3Health News:'Network' approach identifies potential breast cancer susceptibility gene 4Health News:Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side 2Health News:Epilepsy Drug Holds Promise as Treatment for Alcoholism 2Health News:Epilepsy Drug Holds Promise as Treatment for Alcoholism 3Health News:Hormone Therapy for Prostate Cancer Linked to Heart Risks 2Health News:Hormone Therapy for Prostate Cancer Linked to Heart Risks 3Health News:Hormone Therapy for Prostate Cancer Linked to Heart Risks 4
... Agarose with low electroendosmosis ... most DNA/RNA applications. If ... to be used as ... ligase and restriction endonucleases, ...
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
... standard gelling temperature, high gel strength agarose ... bp. This Genetic Technology Grade™ (GTG) agarose ... DNA recovered from SeaKem GTG Agarose gels ... GTG Agarose is extensively performance tested to ...
This agarose provides superior resolution of small PCR fragments and primers at lower concentrations than standard agaroses. A 3% gel clearly resolves a 10 bp ladder, and a 4% gel approaches the reso...
Medicine Products: